参考文献:
[1]. 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第四版). 中华神经科杂志. 2020,53(12): 973-986.
[2]. Tran TN, Vo TNN, Frei K, et al. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm (Vienna). 2018;125(8):1109-1117.
[3]. Kum WF, Gao J, Durairajan SS, et al. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease. J Clin Neurosci. 2009;16(8):1034-1037.
[4]. 陈生弟. 帕金森病运动并发症的防治策略. 中华老年医学杂志, 2016, 35(004):343-346.
[5]. 冯涛, 王拥军. 持续性多巴胺能刺激治疗帕金森病的研究进展. 临床神经病学杂志, 2008, 21(4):315-317.
[6]. Stocchi F. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S68-71.
[7]. Chondrogiorgi M, Tatsioni A, Reichmann H, et al. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. Eur J Neurol,2014,21: 433-440.
[8]. 盐酸普拉克索片说明书. 2020年版
[9]. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-1266.
[10]. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013 Jan; 20(1): 5-15.
[11]. 刘玉丽. 盐酸普拉克索缓释片的临床应用进展. 国际药学研究杂志, 2014, 41: 98-101.
[12]. 王鲁宁, 邹永明,刘丽欣. 普拉克索:帕金森病治疗的新选择. 中国药物应用与监测, 2013, (1):1-4.
[13]. Jenner P, Könen-Bergmann M, Schepers C, et al. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clinical therapeutics.2009;31(11):2698-2711.
[14]. Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. Mov Disord. 2010 Oct 30;25(14):2326-32.
[15]. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000, 284: 1931-1938.
[16]. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol,2009,66:563-570.
[17]. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166.
[18]. Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23;77(8):767-74.
[19]. Mizuno Y, Yamamoto M, Kuno S, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35(4):174-181.
[20]. Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord. 2010;25(15):2542-2549.
[21]. Wang Y, Sun S, Zhu S, et al. The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study. Translational Neurodegeneration. 2014, 3:11.
[22]. Shen Z, Kong D. Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease. Medicine (Baltimore). 2018 Aug;97(34):e11316.
[23]. Rizos A, Sauerbier A, Antonini A, et al. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016 Aug;23(8):1255-61.
[24]. Pellicano C, Benincasa D, Fanciulli A, et al. The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study. Eur J Med Res. 2013 Dec 21;18:60.
[25]. Schapira AH, Barone P, Hauser RA, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol. 2013; 20(1): 50-6.
[26]. Chan KA, Hsieh YC, Hsieh SF, et al. Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan. Drugs Real World Outcomes. 2021;8(1):63-71.